+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Metabolic Disorders Therapeutics Market by Treatment Classifications, Disease Type, Therapeutic Areas, Route Of Administration, Patient Demographics, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Metabolic Disorders Therapeutics Market by Treatment Classifications, Disease Type, Therapeutic Areas, Route Of Administration, Patient Demographics, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Metabolic Disorders Therapeutics Market by Treatment Classifications, Disease Type, Therapeutic Areas, Route Of Administration, Patient Demographics, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 183 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968659
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The metabolic disorders therapeutics market is evolving, presenting both new opportunities and challenges for businesses, investors, and healthcare leaders. This overview highlights strategic market factors, innovation trends, and actionable insights that drive decision-making for stakeholders across the global life sciences landscape.

Market Snapshot: Metabolic Disorders Therapeutics Market Overview

The Metabolic Disorders Therapeutics Market grew from USD 75.55 billion in 2024 to USD 81.80 billion in 2025. It is projected to reach USD 122.49 billion by 2030, expanding at a CAGR of 8.38%. Industry momentum is fueled by advances in biotechnology, gene therapies, and patient-centric care innovation. Shifting clinical approaches, evolving regulatory frameworks, and dynamic supply chain considerations are reshaping the competitive landscape for key players and emerging companies alike.

Scope & Segmentation

This report delivers comprehensive analysis and forward-looking segmentation across multiple dimensions essential for senior leaders:

  • Treatment Classifications: Enzyme replacement therapies, gene therapies, medications & drugs, small molecule therapy
  • Disease Types: Diabetes mellitus (including gestational, type 1, and type 2), Gaucher’s disease, hemochromatosis, hypercholesterolemia, mitochondrial disorders, phenylketonuria (PKU), Pompe disease, thyroid disorders (hyper- and hypo-), urea cycle disorders, Wilson's disease
  • Therapeutic Areas: Endocrine disorders, genetic disorders, nutritional disorders
  • Route of Administration: Intravenous, oral, subcutaneous
  • Patient Demographics: Adult patients, geriatric patients, pediatric patients
  • End Users: Clinics, homecare settings, hospitals, specialty centers
  • Distribution Channels: Hospital pharmacies, online pharmacies, retail pharmacies
  • Regional Coverage: Americas (U.S. and key states, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including key markets such as the UK, Germany, France, Saudi Arabia, and others), Asia-Pacific (including China, India, Japan, Australia, and others)
  • Key Companies Profiled: Strategic focus on over 30 leading biopharmaceutical companies, including Abbott Laboratories, Novo Nordisk A/S, Amgen Inc., AstraZeneca plc, Sanofi S.A., and others

Key Takeaways for Decision-Makers

  • Gene editing and targeted enzyme replacement are advancing therapeutic standards, enabling interventions at the molecular level.
  • Precision medicine is driving industry R&D toward patient-specific solutions, improving outcomes and supporting expanded indications.
  • Regulatory flexibility has streamlined the approval of innovative therapies, shortening time-to-market in high unmet-need areas.
  • Emerging RNA-targeted therapies and advanced delivery systems are projected to further transform both chronic and rare disease management.
  • Regional policies and distinct payer models are influencing access, competitive strategies, and alliance formation across major geographies.
  • Collaboration with patient advocacy organizations supports trust-building and engagement, shaping commercialization alignment and uptake.

Tariff Impact on Supply Chain and Cost Structure

Recent United States tariff changes, beginning in 2025, are altering cost structures within the metabolic disorder therapeutics supply chain. Increased duties on active pharmaceutical ingredients and finished formulations are prompting manufacturers to reassess global sourcing, seek tariff waivers, or invest in local production. Healthcare providers and distributors are adopting dynamic procurement strategies, including long-term pricing contracts and domestic manufacturing partnerships, to maintain stability and continuity of patient access. These shifts are driving a trend toward enhanced supply resilience and triggering a gradual redistribution of production facilities.

Methodology & Data Sources

This report leverages a mixed-methods framework, combining quantitative analysis with qualitative perspectives. Data are sourced from primary interviews with industry executives and clinicians, and validated through secondary sources such as journals, regulatory filings, patent databases, and clinical trial portals. Robust statistical modeling and scenario analysis underpin segmentation and trade policy impacts.

Why This Report Matters

  • Aligns innovation and strategic planning with evolving therapeutic trends, regulatory scenarios, and competitive dynamics.
  • Empowers executives to optimize geographic and segment-specific initiatives, strengthening go-to-market tactics and partnership development.
  • Provides actionable recommendations on product development, supply chain risk mitigation, and cross-functional collaboration to address market volatility.

Conclusion

The metabolic disorders therapeutics landscape is shifting in response to innovation, policy developments, and evolving models of care. Leaders prepared to integrate new technologies and adaptive strategies will be positioned to create sustainable value and competitive differentiation.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of dual GLP-1 and GIP receptor agonists for enhanced glycemic control and weight management
5.2. Growing development of oral small molecule glucokinase activators for improved insulin secretion and safety
5.3. Increasing focus on microbiome-targeted therapies to modulate metabolic pathways in obesity treatment
5.4. Advances in precision medicine integrating genetic profiling for personalized metabolic disorder interventions
5.5. Adoption of continuous glucose monitoring paired with AI analytics to optimize diabetes management
5.6. Expansion of combination therapies targeting lipid metabolism and insulin resistance in NASH patients
5.7. Progress in peptide-based dual amylin and calcitonin receptor agonists for obesity management
5.8. Development of non-invasive neurostimulation devices to regulate appetite and energy balance
5.9. Rising interest in SGLT2 inhibitors for cardiometabolic benefits beyond glycemic control
5.10. Integration of telehealth platforms with digital therapeutics for remote metabolic disorder management
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Metabolic Disorders Therapeutics Market, by Treatment Classifications
8.1. Introduction
8.2. Enzyme Replacement Therapies
8.3. Gene Therapies
8.4. Medications & Drugs
8.5. Small Molecule Therapy
9. Metabolic Disorders Therapeutics Market, by Disease Type
9.1. Introduction
9.2. Diabetes Mellitus
9.2.1. Gestational Diabetes
9.2.2. Type 1 Diabetes
9.2.3. Type 2 Diabetes
9.3. Gaucher’s Disease
9.4. Hemochromatosis
9.5. Hypercholesterolemia
9.6. Mitochondrial Disorders
9.7. Phenylketonuria (PKU)
9.8. Pompe Disease
9.9. Thyroid Disorders
9.9.1. Hyperthyroidism
9.9.2. Hypothyroidism
9.10. Urea Cycle Disorders
9.11. Wilson's Disease
10. Metabolic Disorders Therapeutics Market, by Therapeutic Areas
10.1. Introduction
10.2. Endocrine Disorders
10.3. Genetic Disorders
10.4. Nutritional Disorders
11. Metabolic Disorders Therapeutics Market, by Route Of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
11.4. Subcutaneous
12. Metabolic Disorders Therapeutics Market, by Patient Demographics
12.1. Introduction
12.2. Adult Patients
12.3. Geriatric Patients
12.4. Pediatric Patients
13. Metabolic Disorders Therapeutics Market, by End User
13.1. Introduction
13.2. Clinics
13.3. Homecare Settings
13.4. Hospitals
13.5. Specialty Centers
14. Metabolic Disorders Therapeutics Market, by Distribution Channel
14.1. Introduction
14.2. Hospital Pharmacies
14.3. Online Pharmacies
14.4. Retail Pharmacies
15. Americas Metabolic Disorders Therapeutics Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Metabolic Disorders Therapeutics Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Metabolic Disorders Therapeutics Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Abbott Laboratories
18.3.2. AbbVie Inc.
18.3.3. Acadia Pharmaceuticals Inc.
18.3.4. Amgen Inc.
18.3.5. Amicus Therapeutics, Inc.
18.3.6. Astellas Pharma Inc.
18.3.7. AstraZeneca plc
18.3.8. Bayer AG
18.3.9. Biocon Limited
18.3.10. BioMarin Pharmaceutical Inc.
18.3.11. Boehringer Ingelheim International GmbH
18.3.12. CHIESI Farmaceutici S.p.A.
18.3.13. Dr. Reddy’s Laboratories Ltd.
18.3.14. Eli Lilly and Company
18.3.15. F. Hoffmann-La Roche Ltd
18.3.16. GlaxoSmithKline PLC
18.3.17. Glenmark Pharmaceuticals Limited
18.3.18. Johnson & Johnson Services, Inc.
18.3.19. Lupin Limited
18.3.20. Luye Pharma Group Ltd
18.3.21. Merck & Co., Inc.
18.3.22. Novartis AG
18.3.23. Novo Nordisk A/S
18.3.24. Otsuka Holdings Co., Ltd.
18.3.25. Pfizer Inc.
18.3.26. Recordati Industria Chimica e Farmaceutica S.p.A
18.3.27. Sanofi S.A.
18.3.28. Sumitomo Pharma Co., Ltd.
18.3.29. Sun Pharmaceutical Industries
18.3.30. Takeda Pharmaceutical Company Limited
18.3.31. Teva Pharmaceutical Industries Ltd.
18.3.32. Torrent Pharmaceuticals Ltd.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. METABOLIC DISORDERS THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. METABOLIC DISORDERS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. METABOLIC DISORDERS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. METABOLIC DISORDERS THERAPEUTICS MARKET: RESEARCHAI
FIGURE 30. METABOLIC DISORDERS THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 31. METABOLIC DISORDERS THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 32. METABOLIC DISORDERS THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. METABOLIC DISORDERS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ENZYME REPLACEMENT THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ENZYME REPLACEMENT THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY MEDICATIONS & DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY MEDICATIONS & DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GAUCHER’S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GAUCHER’S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HEMOCHROMATOSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HEMOCHROMATOSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY MITOCHONDRIAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY MITOCHONDRIAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PHENYLKETONURIA (PKU), BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PHENYLKETONURIA (PKU), BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY POMPE DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY POMPE DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERTHYROIDISM, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERTHYROIDISM, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPOTHYROIDISM, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPOTHYROIDISM, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY UREA CYCLE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY UREA CYCLE DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY WILSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY WILSON'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ENDOCRINE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ENDOCRINE DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY NUTRITIONAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY NUTRITIONAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 137. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2024 (USD MILLION)
TABLE 138. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2025-2030 (USD MILLION)
TABLE 139. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 140. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 141. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2024 (USD MILLION)
TABLE 142. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2025-2030 (USD MILLION)
TABLE 143. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2024 (USD MILLION)
TABLE 144. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2025-2030 (USD MILLION)
TABLE 145. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 146. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 147. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 148. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 149. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 150. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 151. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 152. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 153. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2024 (USD MILLION)
TABLE 156. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2025-2030 (USD MILLION)
TABLE 157. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 158. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 159. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2024 (USD MILLION)
TABLE 160. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2025-2030 (USD MILLION)
TABLE 161. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2024 (USD MILLION)
TABLE 162. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2025-2030 (USD MILLION)
TABLE 163. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 164. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 165. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 166. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 167. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 168. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 169. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2025-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 238. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 240. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 242. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 244. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2024 (USD MILLION)
TABLE 248. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2025-2030 (USD MILLION)
TABLE 249. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 250. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 251. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2024 (USD MILLION)
TABLE 252. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2025-2030 (USD MILLION)
TABLE 253. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2024 (USD MILLION)
TABLE 254. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2025-2030 (USD MILLION)
TABLE 255. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 256. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 257. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 258. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 259. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 260. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 261. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2024 (USD MILLION)
TABLE 266. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2025-2030 (USD MILLION)
TABLE 267. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 268. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 269. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2024 (USD MILLION)
TABLE 270. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2025-2030 (USD MILLION)
TABLE 271. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2024 (USD MILLION)
TABLE 272. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2025-2030 (USD MILLION)
TABLE 273. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
TABLE 274. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
TABLE 275. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 276. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 277. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 278. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 279. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 280. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 281. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 282. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 283. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2024 (USD MILLION)
TABLE 284. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2025-2030 (USD MILLION)
TABLE 285. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 286. RUSSIA METABOLIC DISORDERS THERAPEU

Samples

Loading
LOADING...

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Acadia Pharmaceuticals Inc.
  • Amgen Inc.
  • Amicus Therapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biocon Limited
  • BioMarin Pharmaceutical Inc.
  • Boehringer Ingelheim International GmbH
  • CHIESI Farmaceutici S.p.A.
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Luye Pharma Group Ltd
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Recordati Industria Chimica e Farmaceutica S.p.A
  • Sanofi S.A.
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.

Table Information

Report AttributeDetails
No. of Pages183
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 81.8 Billion
Forecasted Market Value ( USD ) by 2030 $ 122.49 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned32

Related Topics

Related Reports

Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report By Disease, By Therapy, By Route Of Administration (Oral, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report By Disease, By Therapy, By Route Of Administration (Oral, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Metabolic Disorder Therapeutics - Global Strategic Business Report - Product Image

Metabolic Disorder Therapeutics - Global Strategic Business Report

  • Report
  • 286 Pages
  • Global
From
Metabolic Disorders Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Metabolic Disorders Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 186 Pages
  • Global
From
Peptide Based Metabolic Disorders Therapeutics Market Report 2025 - Product Image

Peptide Based Metabolic Disorders Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Isovaleric Acidemia (IVA) Treatment Global Market Report 2025 - Product Image

Isovaleric Acidemia (IVA) Treatment Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From

About the Metabolic Disorder Drug Market

The Metabolic Disorder Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market. It includes drugs used to treat metabolic disorders such as diabetes, obesity, and hyperlipidemia. These drugs are used to regulate the body's metabolism, which is the process of converting food into energy. Common drugs used to treat metabolic disorders include insulin, sulfonylureas, biguanides, thiazolidinediones, and GLP-1 agonists. These drugs are used to control blood sugar levels, reduce cholesterol, and promote weight loss. The Metabolic Disorder Drug market is highly competitive, with many companies offering a variety of drugs to treat metabolic disorders. Some of the major players in the market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. Other companies in the market include Boehringer Ingelheim, Takeda, and Pfizer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.